Skip to main content
SpringerLink
Log in

Point-of-Care Clinical Guide: Cholangiocarcinoma

  • Chapter
  • First Online:
Pancreas and Biliary Disease

  • 1097 Accesses

Abstract

Cholangiocarcinoma is a neoplasm arising from the epithelial lining of the biliary tree; the cholangiocytes. Cholangiocarcinoma encompasses three types based on anatomical location: intrahepatic (IHCC), extrahepatic (EHCC), and hilar (HiCC) type; with the hilar type being the most common. Although cholangiocarcinoma is a rare tumor, its incidence is rising worldwide. Late presentation of the disease contributes to the poor prognosis and occurs due to subtle symptoms that often initially go unrecognized. Although surgical resection remains the best available option for cholangiocarcinoma, late presentation can limit surgical resection as an option, stressing the need for alternative interventions. Current therapeutic options include resection, liver transplantation, systematic chemotherapy, radiotherapy, and liver directed therapies. Palliative care is a valuable tool for those entering a non-curative paradigm in order to potentially minimize symptoms and improve the patient’s quality of life. In this chapter, we discuss factors most commonly associated with disease development, available treatments, and anticipated outcomes for cholangiocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis. 1994;14(2):109–14.

    Article  CAS  PubMed  Google Scholar 

  2. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24(2):115–25.

    Article  PubMed  Google Scholar 

  3. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology. 2005;128(3):620–6.

    Article  PubMed  Google Scholar 

  4. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5):755–62.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002;51 Suppl 6:VI1–9.

    PubMed  PubMed Central  Google Scholar 

  6. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37(6):806–13.

    Article  PubMed  Google Scholar 

  7. Jepsen P, Vilstrup H, Tarone RE, Friis S, Sørensen HT. Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002. J Natl Cancer Inst. 2007;99(11):895–7.

    Article  PubMed  Google Scholar 

  8. West J, Wood H, Logan RF, Quinn M, Aithal GP. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer. 2006;94(11):1751–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002;2:10.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Strom BL, Hibberd PL, Soper KA, Stolley PD, Nelson WL. International variations in epidemiology of cancers of the extrahepatic biliary tract. Cancer Res. 1985;45(10):5165–8.

    CAS  PubMed  Google Scholar 

  11. Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61(12):1657–69.

    Article  CAS  PubMed  Google Scholar 

  12. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.

    Article  PubMed  Google Scholar 

  13. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med. 1995;332(14):924–33.

    Article  CAS  PubMed  Google Scholar 

  14. Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ, LaRusso NF. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg. 1991;213(1):21–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Lööf L, Danielsson A, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36(3):321–7.

    Article  PubMed  Google Scholar 

  16. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99(3):523–6.

    Article  PubMed  Google Scholar 

  17. Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58(6):2045–55.

    Article  CAS  PubMed  Google Scholar 

  18. Cheon YK, Lee TY, Lee SM, Yoon JY, Shim CS. Longterm outcome of photodynamic therapy compared with biliary stenting alone in patients with advanced hilar cholangiocarcinoma. HPB (Oxford). 2012;14(3):185–93.

    Article  Google Scholar 

  19. Shin HR, Lee CU, Park HJ, Seol SY, Chung JM, Choi HC, et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan. Korea Int J Epidemiol. 1996;25(5):933–40.

    Article  CAS  PubMed  Google Scholar 

  20. Watanapa P. Cholangiocarcinoma in patients with opisthorchiasis. Br J Surg. 1996;83(8):1062–4.

    Article  CAS  PubMed  Google Scholar 

  21. Watanapa P, Watanapa WB. Liver fluke-associated cholangiocarcinoma. Br J Surg. 2002;89(8):962–70.

    Article  CAS  PubMed  Google Scholar 

  22. Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol. 2008;24(3):349–56.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Su CH, Shyr YM, Lui WY, P'Eng FK. Hepatolithiasis associated with cholangiocarcinoma. Br J Surg. 1997;84(7):969–73.

    Article  CAS  PubMed  Google Scholar 

  24. Chijiiwa K, Yamashita H, Yoshida J, Kuroki S, Tanaka M. Current management and long-term prognosis of hepatolithiasis. Arch Surg. 1995;130(2):194–7.

    Article  CAS  PubMed  Google Scholar 

  25. Donato F, Gelatti U, Tagger A, Favret M, Ribero ML, Callea F, et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control. 2001;12(10):959–64.

    Article  CAS  PubMed  Google Scholar 

  26. Jan YY, Chen MF, Wang CS, Jeng LB, Hwang TL, Chen SC. Surgical treatment of hepatolithiasis: long-term results. Surgery. 1996;120(3):509–14.

    Article  CAS  PubMed  Google Scholar 

  27. Scott J, Shousha S, Thomas HC, Sherlock S. Bile duct carcinoma: a late complication of congenital hepatic fibrosis. Case report and review of literature. Am J Gastroenterol. 1980;73(2):113–9.

    CAS  PubMed  Google Scholar 

  28. Lipsett PA, Pitt HA, Colombani PM, Boitnott JK, Cameron JL. Choledochal cyst disease. A changing pattern of presentation. Ann Surg. 1994;220(5):644–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Ohtsuka T, Inoue K, Ohuchida J, Nabae T, Takahata S, Niiyama H, et al. Carcinoma arising in choledochocele. Endoscopy. 2001;33(7):614–9.

    Article  CAS  PubMed  Google Scholar 

  30. Goto N, Yasuda I, Uematsu T, Kanemura N, Takao S, Ando K, et al. Intrahepatic cholangiocarcinoma arising 10 years after the excision of congenital extrahepatic biliary dilation. J Gastroenterol. 2001;36(12):856–62.

    Article  CAS  PubMed  Google Scholar 

  31. Dayton MT, Longmire WP, Tompkins RK. Caroli's Disease: a premalignant condition? Am J Surg. 1983;145(1):41–8.

    Article  CAS  PubMed  Google Scholar 

  32. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366(9493):1303–14.

    Article  PubMed  Google Scholar 

  33. Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol. 1999;10 Suppl 4:308–11.

    Article  PubMed  Google Scholar 

  34. Sahani D, Prasad SR, Tannabe KK, Hahn PF, Mueller PR, Saini S. Thorotrast-induced cholangiocarcinoma: case report. Abdom Imaging. 2003;28(1):72–4.

    Article  CAS  PubMed  Google Scholar 

  35. Rubel LR, Ishak KG. Thorotrast-associated cholangiocarcinoma: an epidemiologic and clinicopathologic study. Cancer. 1982;50(7):1408–15.

    Article  CAS  PubMed  Google Scholar 

  36. Lipshutz GS, Brennan TV, Warren RS. Thorotrast-induced liver neoplasia: a collective review. J Am Coll Surg. 2002;195(5):713–8.

    Article  PubMed  Google Scholar 

  37. Mitacek EJ, Brunnemann KD, Hoffmann D, Limsila T, Suttajit M, Martin N, et al. Volatile nitrosamines and tobacco-specific nitrosamines in the smoke of Thai cigarettes: a risk factor for lung cancer and a suspected risk factor for liver cancer in Thailand. Carcinogenesis. 1999;20(1):133–7.

    Article  CAS  PubMed  Google Scholar 

  38. Szendröi M, Németh L, Vajta G. Asbestos bodies in a bile duct cancer after occupational exposure. Environ Res. 1983;30(2):270–80.

    Article  PubMed  Google Scholar 

  39. Sorensen HT, Friis S, Olsen JH, Thulstrup AM, Mellemkjaer L, Linet M, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology. 1998;28(4):921–5.

    Article  CAS  PubMed  Google Scholar 

  40. Kobayashi M, Ikeda K, Saitoh S, Suzuki F, Tsubota A, Suzuki Y, et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer. 2000;88(11):2471–7.

    Article  CAS  PubMed  Google Scholar 

  41. Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol. 2012;57(1):69–76.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Zhou Y, Zhao Y, Li B, Huang J, Wu L, Xu D, et al. Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis. BMC Cancer. 2012;12:289.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Li M, Li J, Li P, Li H, Su T, Zhu R, et al. Hepatitis B virus infection increases the risk of cholangiocarcinoma: a meta-analysis and systematic review. J Gastroenterol Hepatol. 2012;27(10):1561–8.

    Article  PubMed  Google Scholar 

  44. Ralphs S, Khan SA. The role of the hepatitis viruses in cholangiocarcinoma. J Viral Hepat. 2013;20(5):297–305.

    Article  CAS  PubMed  Google Scholar 

  45. Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29(2):221–32.

    Article  PubMed  Google Scholar 

  46. Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology. 2000;31(1):7–11.

    Article  CAS  PubMed  Google Scholar 

  47. Bergquist A, Glaumann H, Persson B, Broomé U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology. 1998;27(2):311–6.

    Article  CAS  PubMed  Google Scholar 

  48. Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007;5(10):1221–8.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224(4):463–73. discussion 73-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Washburn WK, Lewis WD, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. Arch Surg. 1995;130(3):270–6.

    Article  CAS  PubMed  Google Scholar 

  51. Slattery JM, Sahani DV. What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma? Oncologist. 2006;11(8):913–22.

    Article  PubMed  Google Scholar 

  52. Abu-Hamda EM, Baron TH. Endoscopic management of cholangiocarcinoma. Semin Liver Dis. 2004;24(2):165–75.

    Article  PubMed  Google Scholar 

  53. Mohamadnejad M, DeWitt JM, Sherman S, LeBlanc JK, Pitt HA, House MG, et al. Role of EUS for preoperative evaluation of cholangiocarcinoma: a large single-center experience. Gastrointest Endosc. 2011;73(1):71–8.

    Article  PubMed  Google Scholar 

  54. El Chafic AH, Dewitt J, Leblanc JK, El Hajj II, Cote G, House MG, et al. Impact of preoperative endoscopic ultrasound-guided fine needle aspiration on postoperative recurrence and survival in cholangiocarcinoma patients. Endoscopy. 2013;45(11):883–9.

    Article  PubMed  Google Scholar 

  55. Strongin A, Singh H, Eloubeidi MA, Siddiqui AA. Role of endoscopic ultrasonography in the evaluation of extrahepatic cholangiocarcinoma. Endosc Ultrasound. 2013;2(2):71–6.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Garrow D, Miller S, Sinha D, Conway J, Hoffman BJ, Hawes RH, et al. Endoscopic ultrasound: a meta-analysis of test performance in suspected biliary obstruction. Clin Gastroenterol Hepatol. 2007;5(5):616–23.

    Article  PubMed  Google Scholar 

  57. Feydy A, Vilgrain V, Denys A, Sibert A, Belghiti J, Vullierme MP, et al. Helical CT assessment in hilar cholangiocarcinoma: correlation with surgical and pathologic findings. AJR Am J Roentgenol. 1999;172(1):73–7.

    Article  CAS  PubMed  Google Scholar 

  58. Soares KC, Kamel I, Cosgrove DP, Herman JM, Pawlik TM. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr. 2014;3(1):18–34.

    PubMed  PubMed Central  Google Scholar 

  59. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–89.

    Article  PubMed  Google Scholar 

  60. Unno M, Okumoto T, Katayose Y, Rikiyama T, Sato A, Motoi F, et al. Preoperative assessment of hilar cholangiocarcinoma by multidetector row computed tomography. J Hepatobiliary Pancreat Surg. 2007;14(5):434–40.

    Article  PubMed  Google Scholar 

  61. Chen HW, Lai EC, Pan AZ, Chen T, Liao S, Lau WY. Preoperative assessment and staging of hilar cholangiocarcinoma with 16-multidetector computed tomography cholangiography and angiography. Hepatogastroenterology. 2009;56(91-92):578–83.

    CAS  PubMed  Google Scholar 

  62. Seo H, Lee JM, Kim IH, Han JK, Kim SH, Jang JY, et al. Evaluation of the gross type and longitudinal extent of extrahepatic cholangiocarcinomas on contrast-enhanced multidetector row computed tomography. J Comput Assist Tomogr. 2009;33(3):376–82.

    Article  PubMed  Google Scholar 

  63. Park MS, Lee DK, Kim MJ, Lee WJ, Yoon DS, Lee SJ, et al. Preoperative staging accuracy of multidetector row computed tomography for extrahepatic bile duct carcinoma. J Comput Assist Tomogr. 2006;30(3):362–7.

    Article  PubMed  Google Scholar 

  64. Bach AM, Hann LE, Brown KT, Getrajdman GI, Herman SK, Fong Y, et al. Portal vein evaluation with US: comparison to angiography combined with CT arterial portography. Radiology. 1996;201(1):149–54.

    Article  CAS  PubMed  Google Scholar 

  65. Materne R, Van Beers BE, Gigot JF, Jamart J, Geubel A, Pringot J, et al. Extrahepatic biliary obstruction: magnetic resonance imaging compared with endoscopic ultrasonography. Endoscopy. 2000;32(1):3–9.

    Article  CAS  PubMed  Google Scholar 

  66. Lomanto D, Pavone P, Laghi A, Panebianco V, Mazzocchi P, Fiocca F, et al. Magnetic resonance-cholangiopancreatography in the diagnosis of biliopancreatic diseases. Am J Surg. 1997;174(1):33–8.

    Article  CAS  PubMed  Google Scholar 

  67. Romagnuolo J, Bardou M, Rahme E, Joseph L, Reinhold C, Barkun AN. Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in suspected biliary disease. Ann Intern Med. 2003;139(7):547–57.

    Article  PubMed  Google Scholar 

  68. Pavone P, Laghi A, Passariello R. MR cholangiopancreatography in malignant biliary obstruction. Semin Ultrasound CT MR. 1999;20(5):317–23.

    Article  CAS  PubMed  Google Scholar 

  69. Kim JY, Kim MH, Lee TY, Hwang CY, Kim JS, Yun SC, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol. 2008;103(5):1145–51.

    Article  PubMed  Google Scholar 

  70. Kluge R, Schmidt F, Caca K, Barthel H, Hesse S, Georgi P, et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology. 2001;33(5):1029–35.

    Article  CAS  PubMed  Google Scholar 

  71. Keiding S, Hansen SB, Rasmussen HH, Gee A, Kruse A, Roelsgaard K, et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology. 1998;28(3):700–6.

    Article  CAS  PubMed  Google Scholar 

  72. Prytz H, Keiding S, Björnsson E, Broomé U, Almer S, Castedal M, et al. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology. 2006;44(6):1572–80.

    Article  CAS  PubMed  Google Scholar 

  73. Ustundag Y, Bayraktar Y. Cholangiocarcinoma: a compact review of the literature. World J Gastroenterol. 2008;14(42):6458–66.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Siqueira E, Schoen RE, Silverman W, Martin J, Rabinovitz M, Weissfeld JL, et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc. 2002;56(1):40–7.

    Article  PubMed  Google Scholar 

  75. Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet. 1975;140(2):170–8.

    CAS  PubMed  Google Scholar 

  76. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am J Med. 1965;38:241–56.

    Article  CAS  PubMed  Google Scholar 

  77. Anderson CD, Pinson CW, Berlin J, Chari RS. Diagnosis and treatment of cholangiocarcinoma. Oncologist. 2004;9(1):43–57.

    Article  PubMed  Google Scholar 

  78. Wade TP, Prasad CN, Virgo KS, Johnson FE. Experience with distal bile duct cancers in U.S. Veterans Affairs hospitals: 1987-1991. J Surg Oncol. 1997;64(3):242–5.

    Article  CAS  PubMed  Google Scholar 

  79. Joseph S, Connor S, Garden OJ. Staging laparoscopy for cholangiocarcinoma. HPB (Oxford). 2008;10(2):116–9.

    Article  CAS  Google Scholar 

  80. Connor S, Barron E, Wigmore SJ, Madhavan KK, Parks RW, Garden OJ. The utility of laparoscopic assessment in the preoperative staging of suspected hilar cholangiocarcinoma. J Gastrointest Surg. 2005;9(4):476–80.

    Article  PubMed  Google Scholar 

  81. Weber SM, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR. Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients. Ann Surg. 2002;235(3):392–9.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Barlow AD, Garcea G, Berry DP, Rajesh A, Patel R, Metcalfe MS, et al. Staging laparoscopy for hilar cholangiocarcinoma in 100 patients. Langenbecks Arch Surg. 2013;398(7):983–8.

    Article  PubMed  Google Scholar 

  83. Lang H, Sotiropoulos GC, Frühauf NR, Dömland M, Paul A, Kind EM, et al. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg. 2005;241(1):134–43.

    PubMed  PubMed Central  Google Scholar 

  84. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84–96.

    Article  PubMed  Google Scholar 

  85. Burke EC, Jarnagin WR, Hochwald SN, Pisters PW, Fong Y, Blumgart LH. Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg. 1998;228(3):385–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BSJ, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234(4):507–17. discussion 17-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Spolverato G, Vitale A, Cucchetti A, Popescu I, Marques HP, Aldrighetti L, et al. Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma? Cancer. 2015;121(22):3998–4006.

    Article  PubMed  Google Scholar 

  88. Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31(9):1188–95.

    Article  PubMed  Google Scholar 

  89. Shirabe K, Shimada M, Harimoto N, Sugimachi K, Yamashita Y, Tsujita E, et al. Intrahepatic cholangiocarcinoma: its mode of spreading and therapeutic modalities. Surgery. 2002;131(1 Suppl):S159–64.

    Article  PubMed  Google Scholar 

  90. de Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29(23):3140–5.

    Article  PubMed  Google Scholar 

  91. Regimbeau JM, Fuks D, Le Treut YP, Bachellier P, Belghiti J, Boudjema K, et al. Surgery for hilar cholangiocarcinoma: a multi-institutional update on practice and outcome by the AFC-HC study group. J Gastrointest Surg. 2011;15(3):480–8.

    Article  PubMed  Google Scholar 

  92. Nguyen KT, Steel J, Vanounou T, Tsung A, Marsh JW, Geller DA, et al. Initial presentation and management of hilar and peripheral cholangiocarcinoma: is a node-positive status or potential margin-positive result a contraindication to resection? Ann Surg Oncol. 2009;16(12):3308–15.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Parikh AA, Abdalla EK, Vauthey JN. Operative considerations in resection of hilar cholangiocarcinoma. HPB (Oxford). 2005;7(4):254–8.

    Article  Google Scholar 

  94. Dinant S, Gerhards MF, Busch OR, Obertop H, Gouma DJ, Van Gulik TM. The importance of complete excision of the caudate lobe in resection of hilar cholangiocarcinoma. HPB (Oxford). 2005;7(4):263–7.

    Article  Google Scholar 

  95. Kow AW, Wook CD, Song SC, Kim WS, Kim MJ, Park HJ, et al. Role of caudate lobectomy in type III A and III B hilar cholangiocarcinoma: a 15-year experience in a tertiary institution. World J Surg. 2012;36(5):1112–21.

    Article  PubMed  Google Scholar 

  96. Wu XS, Dong P, Gu J, Li ML, Wu WG, Lu JH, et al. Combined portal vein resection for hilar cholangiocarcinoma: a meta-analysis of comparative studies. J Gastrointest Surg. 2013;17(6):1107–15.

    Article  PubMed  Google Scholar 

  97. de Jong MC, Marques H, Clary BM, Bauer TW, Marsh JW, Ribero D, et al. The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. Cancer. 2012;118(19):4737–47.

    Article  PubMed  Google Scholar 

  98. Hemming AW, Mekeel K, Khanna A, Baquerizo A, Kim RD. Portal vein resection in management of hilar cholangiocarcinoma. J Am Coll Surg. 2011;212(4):604–13. discussion 13-6.

    Article  PubMed  Google Scholar 

  99. Ito K, Ito H, Allen PJ, Gonen M, Klimstra D, D'Angelica MI, et al. Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. Ann Surg. 2010;251(4):675–81.

    Article  PubMed  Google Scholar 

  100. Hong SM, Pawlik TM, Cho H, Aggarwal B, Goggins M, Hruban RH, et al. Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma. Surgery. 2009;146(2):250–7.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Shimoda M, Farmer DG, Colquhoun SD, Rosove M, Ghobrial RM, Yersiz H, et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl. 2001;7(12):1023–33.

    Article  CAS  PubMed  Google Scholar 

  102. Fu BS, Zhang T, Li H, Yi SH, Wang GS, Xu C, et al. The role of liver transplantation for intrahepatic cholangiocarcinoma: a single-center experience. Eur Surg Res. 2011;47(4):218–21.

    Article  PubMed  Google Scholar 

  103. Robles R, Figueras J, Turrión VS, Margarit C, Moya A, Varo E, et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg. 2004;239(2):265–71.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Friman S, Foss A, Isoniemi H, Olausson M, Höckerstedt K, Yamamoto S, et al. Liver transplantation for cholangiocarcinoma: selection is essential for acceptable results. Scand J Gastroenterol. 2011;46(3):370–5.

    Article  PubMed  Google Scholar 

  105. Gores GJ, Nagorney DM, Rosen CB. Cholangiocarcinoma: is transplantation an option? For whom? J Hepatol. 2007;47(4):455–9.

    Article  PubMed  Google Scholar 

  106. Darwish Murad S, Kim WR, Therneau T, Gores GJ, Rosen CB, Martenson JA, et al. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology. 2012;56(3):972–81.

    Article  PubMed  Google Scholar 

  107. Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143(1):88–98. e3; quiz e14.

    Article  PubMed  Google Scholar 

  108. Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005;242(3):451–8. discussion 8-61.

    PubMed  PubMed Central  Google Scholar 

  109. Rao S, Cunningham D, Hawkins RE, Hill ME, Smith D, Daniel F, et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer. 2005;92(9):1650–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Ducreux M, Van Cutsem E, Van Laethem JL, Gress TM, Jeziorski K, Rougier P, et al. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer. 2005;41(3):398–403.

    Article  CAS  PubMed  Google Scholar 

  111. Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. Oncologist. 2008;13(4):415–23.

    Article  CAS  PubMed  Google Scholar 

  112. Gallardo JO, Rubio B, Fodor M, Orlandi L, Yáñez M, Gamargo C, et al. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol. 2001;12(10):1403–6.

    Article  CAS  PubMed  Google Scholar 

  113. Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology. 2001;48(39):783–9.

    CAS  PubMed  Google Scholar 

  114. Tsavaris N, Kosmas C, Gouveris P, Gennatas K, Polyzos A, Mouratidou D, et al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs. 2004;22(2):193–8.

    Article  CAS  PubMed  Google Scholar 

  115. Androulakis N, Aravantinos G, Syrigos K, Polyzos A, Ziras N, Tselepatiotis E, et al. Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study. Oncology. 2006;70(4):280–4.

    Article  CAS  PubMed  Google Scholar 

  116. André T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004;15(9):1339–43.

    Article  PubMed  Google Scholar 

  117. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol. 2005;23(10):2332–8.

    Article  CAS  PubMed  Google Scholar 

  118. Cho JY, Paik YH, Chang YS, Lee SJ, Lee DK, Song SY, et al. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer. 2005;104(12):2753–8.

    Article  CAS  PubMed  Google Scholar 

  119. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14): 1273–81.

    Article  CAS  PubMed  Google Scholar 

  120. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103(4):469–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Yang R, Wang B, Chen YJ, Li HB, Hu JB, Zou SQ. Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a meta-analysis. Anticancer Drugs. 2013;24(8):871–7.

    Article  CAS  PubMed  Google Scholar 

  122. Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol. 2011;18(3):651–8.

    Article  PubMed  Google Scholar 

  123. Dumitrascu T, Chirita D, Ionescu M, Popescu I. Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome. J Gastrointest Surg. 2013;17(5):913–24.

    Article  PubMed  Google Scholar 

  124. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934–40.

    Article  PubMed  Google Scholar 

  125. Miura JT, Johnston FM, Tsai S, George B, Thomas J, Eastwood D, et al. Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2015;22(11):3716–23.

    Article  PubMed  Google Scholar 

  126. Cameron JL, Pitt HA, Zinner MJ, Kaufman SL, Coleman J. Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. Am J Surg. 1990;159(1):91–7. discussion 7-8.

    Article  CAS  PubMed  Google Scholar 

  127. Pitt HA, Nakeeb A, Abrams RA, Coleman J, Piantadosi S, Yeo CJ, et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg. 1995;221(6):788–97. discussion 97-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Kamada T, Saitou H, Takamura A, Nojima T, Okushiba SI. The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys. 1996;34(4):767–74.

    Article  CAS  PubMed  Google Scholar 

  129. Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashiwagi H, et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys. 2000;46(3):581–7.

    Article  CAS  PubMed  Google Scholar 

  130. Gerhards MF, van Gulik TM, González González D, Rauws EA, Gouma DJ. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg. 2003;27(2):173–9.

    PubMed  Google Scholar 

  131. Ben-Josef E, Normolle D, Ensminger WD, Walker S, Tatro D, Ten Haken RK, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005;23(34):8739–47.

    Article  PubMed  Google Scholar 

  132. Kopek N, Holt MI, Hansen AT, Høyer M. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol. 2010;94(1):47–52.

    Article  PubMed  Google Scholar 

  133. Polydorou AA, Cairns SR, Dowsett JF, Hatfield AR, Salmon PR, Cotton PB, et al. Palliation of proximal malignant biliary obstruction by endoscopic endoprosthesis insertion. Gut. 1991;32(6):685–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Goenka MK, Goenka U. Palliation: Hilar cholangiocarcinoma. World J Hepatol. 2014;6(8):559–69.

    PubMed  PubMed Central  Google Scholar 

  135. Blumgart LH, Hadjis NS, Benjamin IS, Beazley R. Surgical approaches to cholangiocarcinoma at confluence of hepatic ducts. Lancet. 1984;1(8368):66–70.

    Article  CAS  PubMed  Google Scholar 

  136. Singhal D, van Gulik TM, Gouma DJ. Palliative management of hilar cholangiocarcinoma. Surg Oncol. 2005;14(2):59–74.

    Article  CAS  PubMed  Google Scholar 

  137. Lai EC, Tang CN. Robot-assisted laparoscopic hepaticojejunostomy for advanced malignant biliary obstruction. Asian J Surg. 2015.

    Google Scholar 

  138. Davids PH, Groen AK, Rauws EA, Tytgat GN, Huibregtse K. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet. 1992;340(8834-8835):1488–92.

    Article  CAS  PubMed  Google Scholar 

  139. Prat F, Chapat O, Ducot B, Ponchon T, Pelletier G, Fritsch J, et al. A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest Endosc. 1998;47(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  140. Raju RP, Jaganmohan SR, Ross WA, Davila ML, Javle M, Raju GS, et al. Optimum palliation of inoperable hilar cholangiocarcinoma: comparative assessment of the efficacy of plastic and self-expanding metal stents. Dig Dis Sci. 2011;56(5):1557–64.

    Article  PubMed  Google Scholar 

  141. Levy MJ, Baron TH, Gostout CJ, Petersen BT, Farnell MB. Palliation of malignant extrahepatic biliary obstruction with plastic versus expandable metal stents: An evidence-based approach. Clin Gastroenterol Hepatol. 2004;2(4):273–85.

    Article  PubMed  Google Scholar 

  142. Sawas T, Al Halabi S, Parsi MA, Vargo JJ. Self-expandable metal stents versus plastic stents for malignant biliary obstruction: a meta-analysis. Gastrointest Endosc. 2015.

    Google Scholar 

  143. Paik WH, Park YS, Hwang JH, Lee SH, Yoon CJ, Kang SG, et al. Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach. Gastrointest Endosc. 2009;69(1):55–62.

    Article  PubMed  Google Scholar 

  144. Nomura T, Shirai Y, Hatakeyama K. Cholangitis after endoscopic biliary drainage for hilar lesions. Hepatogastroenterology. 1997;44(17):1267–70.

    CAS  PubMed  Google Scholar 

  145. De Palma GD, Galloro G, Siciliano S, Iovino P, Catanzano C. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc. 2001;53(6):547–53.

    Article  PubMed  Google Scholar 

  146. Ridtitid W, Rerknimitr R, Janchai A, Kongkam P, Treeprasertsuk S, Kullavanijaya P. Outcome of second interventions for occluded metallic stents in patients with malignant biliary obstruction. Surg Endosc. 2010;24(9):2216–20.

    Article  PubMed  Google Scholar 

  147. Liberato MJ, Canena JM. Endoscopic stenting for hilar cholangiocarcinoma: efficacy of unilateral and bilateral placement of plastic and metal stents in a retrospective review of 480 patients. BMC Gastroenterol. 2012;12:103.

    Article  PubMed  PubMed Central  Google Scholar 

  148. Ortner MA, Liebetruth J, Schreiber S, Hanft M, Wruck U, Fusco V, et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology. 1998;114(3):536–42.

    Article  CAS  PubMed  Google Scholar 

  149. Ortner ME, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology. 2003;125(5):1355–63.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, The Medical College of Wisconsin, 9200 West Wisconsin Ave., Milwaukee, WI, USA

    Abdulrahman Y. Hammad M.D., Nicholas G. Berger M.D. & T. Clark Gamblin M.D., M.S., M.B.A.

Authors
  1. Abdulrahman Y. Hammad M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas G. Berger M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Clark Gamblin M.D., M.S., M.B.A.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Clark Gamblin M.D., M.S., M.B.A. .

Editor information

Editors and Affiliations

  1. Division of Gastroenterology & Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

    Kulwinder Dua

  2. Division of Gastroenterology & Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

    Reza Shaker

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Hammad, A.Y., Berger, N.G., Gamblin, T.C. (2016). Point-of-Care Clinical Guide: Cholangiocarcinoma. In: Dua, K., Shaker, R. (eds) Pancreas and Biliary Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-28089-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-28089-9_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-28087-5

  • Online ISBN: 978-3-319-28089-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation